Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
10 p, 856.3 KB Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor / Sureda, A. (Institut Català d'Oncologia) ; Chabannon, Christian (Institut Paoli-Calmettes) ; Masszi, T. (Semmelweis University) ; Pohlreich, D. (Charles University Hospital) ; Scheid, C. (University of Cologne) ; Thieblemont, C. (Hôpital Saint-Louis) ; Wahlin, B.E. (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Sakellari, I. (George Papanicolaou General Hospital) ; Russell, N. (Nottingham University Hospital) ; Janikova, A. (University Hospital Brno (República Txeca)) ; Dabrowska-Iwanicka, A. (Maria Sklodowska-Curie Institute-Oncology Center) ; Touzeau, Cyrille (CHU Nantes) ; Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ; Jantunen, E. (University of Eastern Finland and Kuopio University Hospital) ; van der Werf, S. (EBMT Data Office) ; Bosman, P. (EBMT Data Office) ; Boumendil, A. (EBMT Statistical Unit) ; Liu, Q. (Sanofi Genzyme) ; Celanovic, M. (Sanofi Genzyme) ; Montoto, S. (St Bartholomew's Hospital) ; Dreger, P. (University of Heidelberg) ; Universitat Autònoma de Barcelona
Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. [...]
2020 - 10.1038/s41409-019-0693-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 613-622  
2.
11 p, 572.5 KB Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group / Mohty, Mohamad (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Malard, F. (Hematology Department. AP-HP. Hôpital Saint-Antoine. Sorbonne Université) ; Abecasis, Manuel (Instituto Portugues de Oncologia) ; Aerts, E. (University Hospital Zurich (Suïssa)) ; Alaskar, A. S. (Department of Oncology. King Abdulaziz Medical City. King Abdullah International Medical Research Center. King Saud Bin Abdulaziz University for Health Sciences. Ministry of National Guard Health Affairs) ; Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre) ; Arat, M. (HSCT Unit. Sisli Florence Nightingale Hospital) ; Bader, Peter (Division for Stem Cell Transplantation and Immunology. Department for Children and Adolescents. University Hospital. Goethe University) ; Baron, Frederic (CHU and University of Liege) ; Basak, G. (Medical University of Warsaw) ; Bazarbachi, A. (American University of Beirut. Department of Internal Medicine) ; Blaise, Didier (Transplant and Cellular Immunotherapy Program. Department of Hematology. Aix-Marseille Univ. Inserm. CNRS. Institut Paoli-Calmettes. CRCM) ; Ciceri, Fabio (Hematology and Bone Marrow Transplantation Unit. IRCCS Ospedale San Raffaele. University Vita-Salute) ; Corbacioglu, Selim (Department of Pediatric Hematology. Oncology and Stem Cell Transplantation. University of Regensburg) ; Dalle, J. H. (Department of Hematology and Immunology. Hospital Robert Debre. Paris 7-Paris Diderot University) ; Dignan, F. (Department of Clinical Haematology. Central Manchester Foundation Trust) ; Fukuda, T. (HSCT Division. National Cancer Center Hospital) ; Huynh, A. (Institut Universitaire du Cancer Toulouse-Oncopole) ; Kuball, J. (Department of Haematology. University Medical Centre) ; Lachance, S. (Department of Hematology and Stem Cell Transplant Program. Hôpital Maisonneuve-Rosemont. University of Montreal) ; Lazarus, H. (Case Western Reserve University) ; Masszi, T. (St László Hospital (Hongria)) ; Michallet, M. (Hematology Department. Groupement Hospitalier Sud. Hospices Civils de Lyon. Université Claude Bernard Lyon EST) ; Nagler, Arnon (Hematology and Bone Marrow Transplantation. Chaim Sheba Medical Center) ; NiChonghaile, M. (Trinity College Dublin) ; Okamoto, S. (Division of Hematology. Department of Medicine. Keio University School of Medicine) ; Pagliuca, A. (King's College Hospital NHS Foundation Trust) ; Peters, C. (Department of Pediatrics. St. Anna Kinderspital) ; Petersen, F. B. (LDS Hospital) ; Richardson, Paul G.. (Division of Hematology. Mayo Clinic) ; Ruutu, T. (Helsinki University Hospital (Finlàndia)) ; Saber, Wael (Center for International Blood and Marrow Transplant Research. Medical College of Wisconsin) ; Savani, B. N. (Hematology and Stem Cell Transplantation Section. Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center and Veterans Affairs Medical Center) ; Soiffer, R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Division of Hematologic Malignancies) ; Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum UMK) ; Wallhult, E. (Sahlgrenska University Hospital (Suècia)) ; Yakoub-Agha, Ibrahim (CHU de Lille. LIRIC INSERM U995. Université de Lille2) ; Duarte, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
2020 - 10.1038/s41409-019-0705-z
Bone marrow transplantation, Vol. 55 Núm. 3 (january 2020) , p. 485-495  
3.
8 p, 788.7 KB A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / Hájek, R. (University Hospital Ostrava) ; Masszi, T. (St László Hospital (Hongria)) ; Petrucci, M. T. (Sapienza Università di Roma) ; Palumbo, A. (Università di Torino) ; Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ; Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ; Yong, K. L. (University College London Cancer Institute) ; Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ; Pour, L. (University Hospital Ostrava) ; Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ; Maisnar, V. (Charles University. Faculty of Medicine in Hradec Králové) ; Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ; Kasparu, H. (Ordensklinikum Linz Elisabethinen) ; Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ; Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ; Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ; Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ; Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ; Dávid, M. (University of Pécs, Hungary) ; de la Rubia, Javier (Hospital Universitari i Politècnic La Fe (València)) ; Drach, J. (Medical University of Vienna) ; Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ; Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ; Leleu, Xavier (Hopital Huriez, CHRU, Lille, France) ; Munder, M. (University Medicine Mainz, Germany) ; Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ; Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ; Rajangam, K. (Onyx Pharmaceuticals, Inc.) ; Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ; San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ; Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria))
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114  

Vea también: autores con nombres similares
4 Masszi, T.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.